NysnoBio

Exciting advances in YOPD research! NysnoBio CEO Jennifer Johnston, PhD, discusses challenges and options that are specific to Young Onset Parkinson's disease patients at this YOPN virtual event. REGISTER NOW. https://yopnetwork.org/event-4899852

New Insight! 💡 NysnoBio SAB member Professor Nobutaka Hattori has published new insight into Parkin activation, and NysnoBio is advancing a potential biomarker based on this work.
nysnobio.com

NysnoBio SAB member Professor Nobutaka Hattori Publishes New Insight into Parkin Activation — NysnoBio Mutations in the genes encoding Parkin/PRKN and PTEN-induced kinase 1 (PINK1) cause selective degeneration of the midbrain dopaminergic neurons in autosomal recessive juvenile parkinsonism (1,2).

Our busy CEO, Dr. Jennifer Johnston, is doing double duty at the 2nd Annual Ligase Targeting Drug Development virtual summit this week! Today she'll be talking small molecules and protein degraders, and tomorrow she leads a roundtable session about today's challenges in the field. Go JJ! 💪
nysnobio.com
ligase-drugdevelopment.com/speaker/jennifer-johnston/
The Ligase Targeting Drug Development summit is an unrivaled forum that unites leading bio industry giants and key academics, enabling them to share unseen data and collaborative efforts, and to discuss the next steps to successfully select, validate and translate E3s into a viable therapy.

NysnoBio's ground-breaking work is going on display: We've been selected as a semi-finalist for the annual BioPitch competition at the BioFlorida conference in Orlando! Every year, the most innovative seed and early-stage life science companies get this promising opportunity to pitch to life science investors. Tomorrow our CEO, Jennifer Johnston, is one of just 16 presenters who will vie for a spot in Friday's finals. Go, JJ! 💪
https://www.bioflorida.com/page/2021BioPitch
https://www.nysnobio.com/